Committed to making a difference for patients, their families and the broader communities affected by sickle cell disease and beta-thalassemia

Our pipeline is built on the differentiated therapeutic potential of our initial product candidate, IMR-687, a highly selective, potent small molecule inhibitor of PDE9. IMR-687 is an oral, once-a-day, potentially disease-modifying treatment for rare hemoglobinopathies.